Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg
tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x
15 mg) dose administration under fasting conditions.